Hematopoiesis News Volume 10.29 | Jul 30 2019

TOP STORY

Cysteine Depletion Targets Leukemia Stem Cells through Inhibition of Electron Transport Complex II

The authors demonstrated that exogenous cysteine was metabolized exclusively to glutathione. Upon cysteine depletion, glutathione synthesis was impaired, leading to reduced glutathionylation of succinate dehydrogenase A, a key component of electron transport chain complex II. [Blood] Abstract | Graphical Abstract

(Ranked by impact factor of the journal)

Entry of the Bat Influenza H17N10 Virus into Mammalian Cells Is Enabled by the MHC Class II HLA-DR Receptor

Researchers observed that certain human hematopoietic cancer cell lines and canine MDCK II cells were susceptible to H17-pseudotyped viruses. They identified the human HLA-DR receptor as an entry mediator for H17 pseudotypes, suggesting that H17N10 possessed zoonotic potential. [Nat Microbiol] Abstract

Erythropoietin Modulates Bone Marrow Stromal Cell Differentiation

ΔEpoR_E mice with erythroid restricted erythropoietin receptor exhibited reduced trabecular bone, increased bone marrow adipocytes, and decreased bone morphogenic protein 2 ectopic bone formation. [Bone Res] Full Article

Soluble SLAMF7 Promotes the Growth of Myeloma Cells via Homophilic Interaction with Surface SLAMF7

Scientists found that sSLAMF7 enhanced the growth of multiple myeloma (MM) cells via homophilic interaction with surface SLAMF7 and subsequent activation of the SHP-2 and ERK signaling pathways. Elotuzumab suppressed soluble SLAMF7-induced MM cell growth both in vitro and in vivo. [Leukemia] Abstract

Autophagy Genes in Myeloid Cells Counteract IFNγ-Induced TNF-Mediated Cell Death and Fatal TNF-Induced Shock

Hypersensitivity of autophagy gene-deficient cells to IFN gamma (IFNγ) was mediated by tumor necrosis factor (TNF) signaling via receptor interacting protein kinase 1- and caspase 8-mediated cell death. [Proc Natl Acad Sci USA] Abstract

Prediction of Venetoclax Activity in Precursor B-ALL by Functional Assessment of Apoptosis Signaling

The authors investigated the activity of the B-cell lymphoma 2 inhibitor venetoclax in B-cell precursor acute lymphoblastic leukemia and found heterogeneous sensitivities in B-cell precursor acute lymphoblastic leukemia cell lines and in a series of patient-derived primografts. [Cell Death Dis] Full Article

Identification of Cross-Reactive Antibodies for the Detection of Lymphocytes, Myeloid Cells and Hematopoietic Precursors in the Naked Mole Rat

Scientists identified ten antibodies recognizing eight immunophenotypic markers expressed on the naked mole rat’s T and B lymphocytes, macrophages/monocytes and putative hematopoietic precursors and used them for an immunophenotyping of leukocyte subsets of peripheral blood, spleen and bone marrow samples. [Eur J Immunol] Abstract

Vitamin C-Dependent Lysine Demethylase 6 (KDM6)-Mediated Demethylation Promotes a Chromatin State That Supports the Endothelial-to-Hematopoietic Transition

Investigators found that endothelial cells generated in the absence of vitamin C failed to undergo the endothelial-to-hematopoietic transition because of an apparent failure in opening up genomic loci essential for hematopoiesis. [J Biol Chem] Abstract | Full Article

Expanded Potential Stem Cell Media as a Tool to Study Human Developmental Hematopoiesis In Vitro

Researchers showed that human pluripotent stem cells (PSCs) maintained in Expanded Potential Stem Cell Medium could spontaneously form embryoid bodies and undergo in vitro hematopoiesis using a simple differentiation protocol, similar to mouse PSC differentiation. [Exp Hematol] Full Article

CLINICAL RESEARCH

Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis

Investigators randomly assigned 154 patients with chronic kidney disease in a 2:1 ratio to receive roxadustat or placebo three times a week for eight weeks in a double-blind manner. The randomized phase of the trial was followed by an 18-week open-label period in which all the patients received roxadustat; parenteral iron was withheld. [N Engl J Med] Abstract

Prognostic Impact of EBV Serostatus in Patients with Lymphomas or Chronic Malignancies Undergoing Allogeneic HCT

The influence of donor and recipient pre-transplant Epstein-Barr Virus (EBV) serostatus on transplant outcomes in 12,931 patients with lymphomas or chronic malignancies undergoing allogeneic hematopoietic cell transplant between 1997–2016 was analyzed. [Bone Marrow Transplant] Abstract

Subscribe to one of our other 19 science newsletters such as Cord Blood News & Cell Therapy News.

Vitiligo Following Stem Cell Transplant

The authors review published literature that has reported the incidence of vitiligo following hematopoietic stem cell transplantation in order to understand their relationship, and any potential connections between vitiligo and graft-versus-host disease. [Bone Marrow Transplant] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Momenta Pharmaceuticals Announces Fast Track Designation for M281 (Nipocalimab) in Hemolytic Disease of the Fetus and Newborn (HDFN)

Momenta Pharmaceuticals, Inc. announced that the FDA has granted Fast Track designation for M281, Momenta’s IgG1 monoclonal antibody targeting FcRn, in HDFN. HDFN is a serious blood disorder in a fetus or newborn that occurs when red cell incompatibility exists between the blood types of a mother and baby. [Momenta Pharmaceuticals, Inc.] Press Release

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Empliciti (Elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone for Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion on a Type-II variation application for Empliciti plus pomalidomide and low-dose dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on the last therapy. [Bristol-Myers Squibb Company] Press Release

Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia

Kura Oncology, Inc. announced that the FDA has granted Orphan Drug Designation to the company’s menin-mixed lineage leukemia inhibitor KO-539 for the treatment of acute myeloid leukemia. [Kura Oncology, Inc.] Press Release

Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Acute Myeloid Leukemia

Mustang Bio, Inc. announced that the FDA has granted Orphan Drug Designation to MB-102 for the treatment of acute myeloid leukemia. The FDA also previously granted Orphan Drug Designation to MB-102 for the treatment of blastic plasmacytoid dendritic cell neoplasm. [Mustang Bio, Inc.] Press Release

Medical Journal Editors Expect Authors to Disclose Conflicts of Interest—But Don’t Disclose Their Own

Virtually all top medical journals require authors to disclose potential conflicts of interest, but few- just 12%- apply that same medicine to their own editors by publicly disclosing editors’ financial ties to industry, a study has found. [ScienceInsider] Editorial

Indonesia Gets Tough on Foreign Scientists

Indonesia’s rich biodiversity and complex geology have lured scientists from abroad for centuries. But a law adopted on 16 July by Indonesia’s parliament may convince some to go elsewhere. The legislation includes strict requirements on foreign scientists doing research in Indonesia, including the need to recruit local collaborators and a near-ban on exporting specimens, along with stiff sanctions, including jail time, for violators. [ScienceInsider] Editorial

NEW 61^st ASH Annual Meeting & Exposition
December 7-10, 2019
Orlando, Florida

Visit our events page to see a complete list of events in the community.

NEW Scientific Communications Coordinator (STEMCELL Technologies Inc.)

NEW PhD Position – Epigenetic Heterogeneity and Dynamics in Acute Myeloid Leukemia (University of Newcastle)

Postdoctoral Position – Genome Editing of Hematopoietic Stem Cells (Bar-Ilan University)

Postdoctoral Position – Advanced Proteomics & Erythropoiesis (Lund University)

Postdoctoral Fellow – Acute Myeloid Leukemia Research (University of Gothenburg)

Faculty Positions – Center for Childhood Cancer and Blood Diseases (The Research Institute at Nationwide Children’s Hospital)

Senior Scientist – Immuno-Oncology of Hematologic Malignancies (University of Kansas School of Medicine)

Postdoctoral Position – Hematopoietic Stem Cell Biology (Columbia University Irving Medical Center)

Postdoctoral Position – Leukemia Research (University of California, San Francisco)

Research Lab Specialist – Tumor Microenvironment & Cell Behavior (University of Southern California)

Senior Lecturer Positions – Clinical Oncology or Hematology (Karolinska Institutet)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here.